Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial

Vaccine

Volumn 33, Issue 32, 2015, Pages 3940-3946

  Wu, Ting ^a   Hu, Yue Mei ^b   Li, Juan ^c   Chu, Kai ^b   Huang, Shou Jie ^a   Zhao, Hui ^c   Wang, Zhong Ze ^d   Yang, Chang Lin ^d   Jiang, Han Min ^d   Wang, Yi Jun ^d   Lin, Zhi Jie ^e   Pan, Hui Rong ^e   Sheng, Wei ^a   Wei, Fei Xue ^a   Li, Shao Wei ^a   Wang, Ying ^f   Zhu, Feng Cai ^b   Li, Chang Gui ^c   Zhang, Jun ^a   Xia, Ning Shao ^a  

^a XIAMEN UNIVERSITY   (China)

^b JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^d Dongtai Center for Disease Control and Prevention   (China)

^e Xiamen Innovax Biotech Company Ltd   (China)

^f China National Center for Biotechnology Development   (China)

Author keywords

Human papillomavirus; Immunogenicity; Randomized controlled clinical trial; Safety; Vaccine

Indexed keywords

HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; IMMUNOGLOBULIN G; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; FATIGUE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; UTERINE CERVIX CANCER; VACCINATION; ADOLESCENT; BLOOD; CHINA; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; IMMUNOLOGY; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHINA; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESCHERICHIA COLI; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOGLOBULIN G; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84937524257     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.052     Document Type: Article

References (25)

1. Bruni L., Barrionuevo-Rosas L., Albero G., Aldea M., Serrano B., Valencia S., et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world 2015, 〈http://www.hpvcentre.net/statistics/reports/XWX.pdf〉 〈accessed 21 Mar 2015〉. Summary Report 2014-12-18.
2. Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations. Vaccine, 2014, http://dx.doi.org/10.1016/j.vaccine.2014.12.002.
3. Group F.I.S. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
4. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perz G., Hareper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
5. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
6. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
7. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372:711-723.
8. Schiller J.T., Castellsague X., Villa L.L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl. 10):K53-K61.
9. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30(Suppl. 5):F139-F148.
10. Hu Y.M., Huang S.J., Chu K., Wu T., Wang Z.Z., Yang C.L., et al. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial. Hum Vaccines Immunother 2014, 10:469-475.
11. Zhao H., Lin Z.J., Huang S.J., Li J., Liu X.H., Guo M., et al. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum Vaccines Immunother 2014, 10:740-746.
12. Guideline for vaccine clinical trial (in Chinese). Available at: http://www.sda.gov.cn/WS01/CL0055/10307.html. Accessed 21 Mar 2015.
13. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008, 105:5850-5855.
14. Schwarz T.F., Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008, 110:S1-S10.
15. Stanley M.A. Immune responses to human papilloma viruses. Indian J Med Res 2009, 130:266-276.
16. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995, 92:11553-11557.
17. World Health Organization Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals 2007, World Health Organization, Available at: 〈http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.05_eng.pdf〉 (accessed 21 Mar 2015).
18. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
19. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccines 2011, 7:1343-1358.
20. Kemp T.J., Garcia-Pineres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26:3608-3616.
21. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
22. Robbins H.A., Kemp T.J., Porras C., Rodriguez A.C., Schiffman M., Wacholder S., et al. Comparison of antibody responses to human papillomavirus vaccination as measured by three assays. Front Oncol 2014, 3:328.
23. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Brit J Cancer 2006, 95:1459-1466.
24. Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11:39-44.
25. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985. GlaxoSmithKline Vaccine HPVSG.